A Phase 1 Study to Evaluate the Safety and Tolerability of a Study Drug in Subjects with Early Alzheimer's Disease (AD)

  • STATUS
    Recruiting
Updated on 19 February 2024

Summary

This study will test the safety and tolerability of an experimental study drug that may delay Alzheimer’s disease (AD) onset or slow the progression of possible AD-related damage due to protein build-up in the brain.   Methods include measuring the amount of study drug and drug-related material in the cerebrospinal fluid (CSF, the fluid surrounding the brain and spinal cord) and blood, and measuring the effect of the study drug on the levels of certain proteins associated with AD in the blood and CSF.

Description

The purpose of this study is to determine the safety and tolerability of multiple doses of Posiphen on subjects with early Alzheimer's Disease (AD) with up to 23-25 days of daily usage, and to implement a lumbar puncture (spinal tap) cerebrospinal fluid (CSF) study. 
Participants will be paid for their participation.

FAQ

Participants will be paid for their participation.

Details
Condition Alzheimer's disease
Age 55years - 85years
Clinical Study IdentifierTX7396
Last Modified on19 February 2024

Eligibility

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team


Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.